<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01692665</url>
  </required_header>
  <id_info>
    <org_study_id>1-2012-0031</org_study_id>
    <nct_id>NCT01692665</nct_id>
  </id_info>
  <brief_title>Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocular aberration may play a role in determining optical quality. Recently performed study&#xD;
      reported that ocular aberration of preocular tear film would be important factor in not only&#xD;
      diagnosing the dry eye but also determining the efficacy of treatment. Therefore, in this&#xD;
      study, the investigators will aim to prove the improvement of quality of vision via ocular&#xD;
      aberration changes indirectly after the proper treatment for moderate and severe meibomian&#xD;
      gland dysfunction. Also, the investigators will evaluate the changes of keratometric values&#xD;
      after treatment for moderate and severe meibomian gland dysfunction, which could be&#xD;
      demonstrated by autokeratometry, IOLMaster, Pentacam, and iTrace.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of keratometric value and ocular aberration</measure>
    <time_frame>a minimum of four minutes, once or twice dailybefore treatment, after 1 month, and after 2 months of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)</condition>
  <arm_group>
    <arm_group_label>stage 3 or stage 4 meibomiang gland dysfunction patients</arm_group_label>
    <description>stage 3 or stage 4 meibomiang gland dysfunction patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        stage 3 or stage 4 meibomiang gland dysfunction patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) stage 3 or 4 meibomian gland dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of previous ocular or intraocular surgery&#xD;
&#xD;
          2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease,&#xD;
&#xD;
          3. history of intolerance or hypersensitivity to any component of the study medications,&#xD;
&#xD;
          4. wearing contact lenses during the study period, presence of current punctal occlusion,&#xD;
&#xD;
          5. pregnancy, lactating women, and children.&#xD;
&#xD;
          6. Additionally, patients were excluded if they were using any topical ocular or systemic&#xD;
             medication that could be used for the treatment MGD or dry eye, including topical or&#xD;
             oral antibiotics, topical cyclosporine A, topical or oral steroids, topical&#xD;
             non-steroidal anti-inflammatory drugs, topical ocular allergy medications or&#xD;
             artificial tears&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>September 16, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meibomian gland dysfunction</keyword>
  <keyword>keratometric value</keyword>
  <keyword>ocular aberration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

